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duration of all LHRH agonist use was 26.3 weeks and 33.2
weeks in younger and older patients, respectively (P  0.05).
LHRH agonists were used for 24 weeks and 48 weeks in
56.4% and 17.6% of younger and in 43.3% and 28.3% of
older patients. Average duration of anti-androgen use for
CAB patients was 34.7 and 39.8 weeks in younger (n  80)
and older patients (n  117, P  ns). Anti-androgens were
used for 24 weeks and 48 weeks in 43.8% and 31.3% of
younger and in 40.2% and 36.8% of older patients.
CONCLUSIONS: The duration of LHRH agonist use by
prostate cancer patients varies by age. Large proportions
of patients in both age groups use CAB for 24 weeks,
suggesting use to protect against testosterone surge. Ad-
ditional research is required to verify these results.
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OBJECTIVES: To compare the efficiency (the evaluation
of efficacy in relation to costs) of three first-line treatment
options for advanced non-small-cell lung cancer (stage IIIB
and IV) used in the ECOG study: docetaxel/cisplatin (75/
75 mg/m2/day; 1 hour IV infusion of docetaxel); paclitaxel/
cisplatin (175/75 mg/m2/day; 3 or 24 hour IV infusion of
paclitaxel), and paclitaxel/carboplatin (175/400 or 225/
400 mg/m2/day; 3 hour IV infusion of paclitaxel).
METHODS: The results of the ECOG 1594 phase III clin-
ical trial demonstrated equivalent efficacy (survival, objec-
tive response) between the treatment options. To differen-
tiate between the treatment options, we performed a cost-
minimization analysis, using a pharmacoeconomic model.
RESULTS: The average estimated treatment cost per patient
(median, four cycles) with docetaxel/cisplatin would be
1,067,836 Spanish pesetas (Ptas) (€6481; 5741 USD),
1,365,304 or 1,439,369 Ptas (€8205 or €8651; 7340 or
7738 USD) with paclitaxel/cisplatin (3 or 24 hour infusions,
respectively), and 1,417,995 or 1,616,784 Ptas (€8522 or
€9717; 7623 or 8692 USD) (paclitaxel dose of 175 or 225
mg/m2/day, respectively) with paclitaxel/carboplatin.
CONCLUSIONS: According to our study, the treatment
option docetaxel/cisplatin, with equal efficacy, would re-
sult in a cost saving of between 297,468 and 548,948
Ptas (1788 and 3299 € or 1599 and 2951 USD) per pa-
tient treated. This difference is mainly due to the lower
treatment cost associated with docetaxel.
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CHEMOTHERAPY-INDUCED NEUROPATHY IN 
OVARIAN CANCER COST 
EFFECTIVENESS ANALYSIS
Hay JW, Patel BV
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OBJECTIVE: Many widely used chemotherapy agents,
including paclitaxel and cisplatin produce neuropathy in
cancer patients. These symptoms are dose-related, some-
times irreversible, and can lead to treatment withdrawal.
To evaluate reported chemotherapy cost-effectiveness, we
assessed the literature on cost and quality of life burden
of chemotherapy-induced neuropathy in ovarian cancer
(OC) patients.
METHODS: MEDLINE was searched for all articles
published in English between 1966 and June 2001 match-
ing neuropathy or cancer with keywords: quality of life;
burden of disease; cost; cost-effectiveness; cost of illness;
indirect cost. Findings from all relevant international stud-
ies were combined to assess neuropathy cost and utility
burden.
RESULTS: Eight hundred eighty four relevant study refer-
ences were identified and reviewed. Only two studies sys-
tematically evaluated the utility loss associated with severe
neuropathy, and only one study reported indirect cost bur-
den of OC neuropathy. No single analysis provided a com-
prehensive assessment of chemotherapy-induced neuropathy
on treatment cost-effectiveness. Clinical evidence suggests
that the burden is substantial. Up to 57% of cisplatin pa-
tients, and 62% of paclitaxel patients experienced significant
neuropathy symptoms. Quality of life decreased by 17–24%
for OC patients experiencing severe neuropathy. Using 2001
US prices and including the indirect costs and quality of life
impacts, the effect of severe neuropathy would be to increase
typically reported base case cost-effectiveness of pacli-
taxel in OC treatment from $33,300/QALY to $52,800/
QALY. Similar results were found for other oncology medi-
cations.
CONCLUSIONS: Neuropathy quality of life and cost
burden has been ignored in the chemotherapy cost-effec-
tiveness literature, because direct treatment costs are
small and quality of life impacts due to neuropathy in
OC patients are rarely explicitly measured. Nevertheless,
this treatment toxicity may have a substantial effect on
chemotherapy cost-effectiveness, possibly increasing re-
ported medication cost/QALY estimates by 60%. More
research is needed to quantify the cost and quality of life
burdens of chemotherapy-induced neuropathy.
PCN15
QOL CHANGE OVER TIME POST-REINFUSION 
OF PBPC IN HIGH DOSE TREATMENT OF NON-
HODGKIN’S FOLLICULAR LYMPHOMA (N-HFL) 
WITH AND WITHOUT FILGRASTIM USE
Van Kriekinge G1, Coiffier B2, Witz B3, Erder HM4, Standaert B1
1Amgen Inc, Brussels, Belgium; 2Centre Hospitalier Lyon Sud, 
Pierre Bénite, France; 3Hôpital Brabois, Vandoeuvre les Nancy, 
France; 4Amgen Inc, Thousand Oaks, CA, USA
OBJECTIVES: To assesses the quality of life (QoL) with
Q-TwiST retrospectively in a randomised phase III trial
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with n-HFL patients comparing the use of filgrastim after
peripheral blood progenitor cells reinfusion.
METHODS: Multi-centre study conducted in France be-
tween 1995-1999 including 51 patients (24 placebo (P)
and 27 filgrastim (FI)). Demographic, disease and treat-
ment-specific information was collected through the
CRF. QoL assessment per patient over 90 days of follow-
up (FU) was calculated as follows. QoL-index valued
from 0 (worst) to 1 (best) was used to assign QoL per
hospital day: in sterile room (SR)  0.6; in a normal
room (NR)  0.9. Each adverse event (AE) (WHO grade
3 or 4) affected the QoL index with an additional factor
of 0.8, 0.6, 0.4 or 0.2 respectively for 1, 2, 3, 	 4 con-
comitant AEs per patient per day. Average QoL-scores
over time per treatment arm were compared using Kaplan-
Meier statistics (p  .05, two-sided). Sensitivity analysis
on the score index over the FU was undertaken.
RESULTS: For FI the average days with 0, 1, 2, 3, 4
AEs in a SR was 6.59, 4, 2.56, 0.81, 0.37 and in a NR,
1.59, 1.67, 0.56, 0.11, 0. For P in a SR we had respec-
tively 8.3, 3.8, 2.8, 2.2, 0.125 and in a NR, 2.13, 0.9, 0,
0, 0. Average estimated QoL-score was 81.71 for FI (SD:
3.15, range: 72.54–85.24) and 80.66 for C (SD: 3.01,
range: 71.8–84.68) (Mann Witney U test: p  0.49 but
decreased to 0.25 for first hospitalization period). Kap-
lan-Meier graph demonstrates after day 16 a constant
QoL benefit for FI due to earlier hospital discharge (Log
rank test: 27.2; p  .001).
CONCLUSION: Filgrastim use 24 hours post-PBPC in
high dose treatment of n-HFL patients is associated with
QoL improvement due to earlier hospital discharge.
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OBJECTIVE: It is assumed that genetic testing for breast-
ovarian cancer predisposition in the context of peer-re-
viewed research protocols at academic centers offers pro-
tection against test-related distress. However, BRCA1/2
genetic testing under research protocols often implies a
significant time delay before the test result can be dis-
closed, which would not apply to commercially available
testing. Using data from our own research setting, we in-
vestigated whether delay in getting BRCA1/2 test results
was associated with participants’ distress.
METHODS: Participants were 128 women from 26
French Canadian kindred with a BRCA1/2 germline mu-
tation identified. Genetic counseling was provided in a
pre-test education session and a result disclosure session.
Of the women tested, 53 (41%) were found to be carriers
of the familial mutation and 75 (59%), non-carriers.
Mean age at enrollment (48.4 yrs 
 12.1) was similar for
the two groups. Test-related distress was assessed by the
Impact of Event Scale one month after result disclosure.
RESULTS: Time interval between blood sample for test-
ing and result disclosure varied considerably (range: 35
to 756 days), and was similar for carriers (mean  172 

120 days) and non-carriers (mean  174 
 174 days).
Among non-carriers, those given their result less than six
months following blood draw (n  48) tended to have
lower levels of test-related distress (mean  3.3 
 5.2)
than those who were told their result beyond 6 months (n 
27, mean  7.8 
 11.2, p  0.06). For carriers, test-
related distress did not differ according to whether they
were given their result less than six months (n  35,
mean  10.4 
 13.7) after the blood draw or later (n 
18, mean  9.8 
 12.2).
CONCLUSIONS: Consistent with others, these results
indicate that most women cope well with test informa-
tion in research settings with careful expert counseling.
Nevertheless, our findings among non-carriers suggest
that prompt disclosure of BRCA1/2 test results has po-
tential quality-of-life benefits.
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OBJECTIVE: The EORTC QLQ-C30 is one of the most
widely used QL measures in cancer clinical trials. This
study aimed to look at the psychometric properties of the
QLQ-C30 in 32 countries with a database of 9000 pa-
tients.
METHOD: All EORTC studies incorporating the EORTC
QLQ-30 were systematically selected for this study. In-
clusion criteria for trials were if the trial containing the
QLQ-C30 responses had been coded into the EORTC
database. One hundred fourteen EORTC studies were re-
viewed of which 52 met the criteria for being included in
the final analysis.
RESULTS: The majority of cancer patients were receiv-
ing palliative care for primary cancers including mela-
noma, prostate, head and neck, breast and lung cancers
and 90% of the patients were distributed over 10 out of
the 32 countries. At least one item of data was missing in
14 to 17% of patient questionnaires completed, though
the average percentage of missing items per patient
ranged from 1.1% to 1.5% Particular items relating to
Role Functioning and Financial Difficulties were the most
common items missing (3%). Factor analyses for all three
versions of the questionnaire are similar, though some
